The SOX (sex-determining region [SRY]-type high mobility group [HMG] box) family of transcription factors play key roles in determining cell fate during organ development. In this study, we have identified a new human SOX gene, S O X 1 3, as encoding the type 1 diabetes autoantigen, islet cell antigen 12 (ICA12). Sequence analysis showed that SOX13 belongs to the class D subgroup of SOX transcription factors, which contain a leucine zipper motif and a region rich in glutamine. SOX13 autoantibodies occurred at a significantly higher frequency among 188 people with type 1 diabetes (18%) than among 88 with type 2 diabetes (6%) or 175 healthy control subjects (4%). Deletion mapping of the antibody epitopes showed that the autoantibodies were primarily directed against an epitope requiring the majority of the protein. S O X 1 3 R N A was detected in most human tissues, with the highest levels in the pancreas, placenta, and kidney. Immunohistochemistry on sections of human pancreas identified SOX13 in the islets of Langerhans, where staining was mostly cytoplasmic. In mouse pancreas, Sox13 was present in the nucleus and cytoplasm of -cells as well as other islet cell types. Recombinant SOX13 protein bound to the SOX consensus DNA motif AACAAT, and binding was inhibited by homodimer formation. These observations-along with the known molecular interactions of the closely related protein, rainbow trout Sox23-suggest that SOX13 may be activated for nuclear import and DNA binding through heterodimer formation. In conclusion, we have identified ICA12 as the putative transcription factor SOX13 and demonstrated an increased frequency of autoantibody reactivity in sera from type 1 diabetic subjects compared with type 2 diabetic and healthy control subjects. T ype 1 diabetes results from the destruction of pancreatic islet -cells by an autoimmune response to -cell constituents, which is initiated by an unknown environmental agent acting on a susceptible genetic background. Identification of GAD (1), a family of tyrosine phosphatase-like proteins variously designated islet cell antigen 512 (ICA512)/IA-2/IA-2 (2,3), and insulin (4) as autoantigens in type 1 diabetes has led to the proposal of several mechanisms for the initiation and progression of islet autoimmunity. These include molecular mimicry between GAD and coxsackievirus B (5) or between ICA512 and rotavirus (6), hyperexpression of GAD in response to metabolic stress (7), and lack of tolerance to (pro)insulin as a consequence of genetic variation of proinsulin expression levels in the thymus (8,9). The multifactorial nature of type 1 diabetes and the association of numerous environmental agents with the disease (10) suggest that there may be multiple pathways leading to -cell autoimm u n i t y. To attain a better understanding of the pathogenesis of type 1 diabetes, the autoimmune response to islet -c e l l s needs to be fully characterized.
The SOX (sex-determining region [SRY]-type high mobility group [HMG] box) family of transcription factors play key roles in determining cell fate during organ development. In this study, we have identified a new human SOX gene, S O X 1 3, as encoding the type 1 diabetes autoantigen, islet cell antigen 12 (ICA12). Sequence analysis showed that SOX13 belongs to the class D subgroup of SOX transcription factors, which contain a leucine zipper motif and a region rich in glutamine. SOX13 autoantibodies occurred at a significantly higher frequency among 188 people with type 1 diabetes (18%) than among 88 with type 2 diabetes (6%) or 175 healthy control subjects (4%). Deletion mapping of the antibody epitopes showed that the autoantibodies were primarily directed against an epitope requiring the majority of the protein. S O X 1 3 R N A was detected in most human tissues, with the highest levels in the pancreas, placenta, and kidney. Immunohistochemistry on sections of human pancreas identified SOX13 in the islets of Langerhans, where staining was mostly cytoplasmic. In mouse pancreas, Sox13 was present in the nucleus and cytoplasm of -cells as well as other islet cell types. Recombinant SOX13 protein bound to the SOX consensus DNA motif AACAAT, and binding was inhibited by homodimer formation. These observations-along with the known molecular interactions of the closely related protein, rainbow trout Sox23-suggest that SOX13 may be activated for nuclear import and DNA binding through heterodimer formation. In conclusion, we have identified ICA12 as the putative transcription factor SOX13 and demonstrated an increased frequency of autoantibody reactivity in sera from type 1 diabetic subjects compared with type 2 diabetic and healthy control subjects. T ype 1 diabetes results from the destruction of pancreatic islet -cells by an autoimmune response to -cell constituents, which is initiated by an unknown environmental agent acting on a susceptible genetic background. Identification of GAD (1), a family of tyrosine phosphatase-like proteins variously designated islet cell antigen 512 (ICA512)/IA-2/IA-2 (2,3), and insulin (4) as autoantigens in type 1 diabetes has led to the proposal of several mechanisms for the initiation and progression of islet autoimmunity. These include molecular mimicry between GAD and coxsackievirus B (5) or between ICA512 and rotavirus (6) , hyperexpression of GAD in response to metabolic stress (7) , and lack of tolerance to (pro)insulin as a consequence of genetic variation of proinsulin expression levels in the thymus (8, 9) . The multifactorial nature of type 1 diabetes and the association of numerous environmental agents with the disease (10) suggest that there may be multiple pathways leading to -cell autoimm u n i t y. To attain a better understanding of the pathogenesis of type 1 diabetes, the autoimmune response to islet -c e l l s needs to be fully characterized.
In a search for novel diabetes-associated autoantigens, the screen of an islet cDNA expression library with type 1 diabetes sera that identified ICA512 also yielded a second clone, designated ICA12, which encoded a protein that reacted with type 1 diabetes sera by Western blot (11) . Here, sequencing of the ICA12 cDNA revealed 99% sequence similarity to the high mobility group (HMG) domain of mouse Sox13 (12, 13) and identified ICA12 as a partial cDNA of the novel human gene SOX13. Sex-determining region Y (SRY)-type HMG box proteins (SOX proteins) are a large family of transcription factors related to the testis-determining factor SRY through their HMG domain (14) , an 80 amino acid motif that binds and bends DNA (15, 16) . Evidence from clinical mutations in S RY, SOX9, a n d SOX10 and gene knockout experiments of S o x 4 in the mouse suggest that SOX proteins play key roles in determining cell fate during organ development (17, 18) . In this article, we describe the gene sequence, expression in human tissues, and biochemical properties of SOX13 and the reactivity of autoantibodies to SOX13 from subjects with diabetes. Our results demonstrate that SOX13 is a minor type 1 diabetes autoantigen expressed in pancreatic islets and would function as a DNA-binding transcription factor through the formation of heterodimers.
RESEARCH DESIGN AND METHODS
DNA cloning and sequencing. The 3.2 kb ICA12.3 cDNA (11) was sequenced using an ABI377 DNA sequencer. The 5 end of human S O X 1 3 was determined by 5 RACE using three antisense primers (SP1 5 G C A G C C A G T T C T T C T G C T; SP2  5 G G A C A A C A G C T T C T C TATGGC; and SP3 5 T C G G T T G A A G T C C A G C T T C T  CC) and a 5 RACE kit (Boehringer Mannheim, Mannheim, Germany) with human placental RNA. Production of recombinant SOX13. Five fragments of the ICA12 cDNA clone derived by polymerase chain reaction were inserted into the E c oR I /S a lI sites of pET23b vector, which contains a T7 epitope tag at the amino terminus (Promega, Madison, WI). They encoded SOX13 (amino acids 66-604), which is the originally described ICA12 clone, and SOX13 LZ-Q (amino acids 327-604), which lacks the leucine zipper domain and the glutamine-rich region. Three further constructs used for epitope mapping were SOX13(66-210), SOX13(209-334), and SOX13(485-604). For expression in bacteria, Escherichia coli BL21 cells were transformed with various pET23b-S O X 1 3 or pT7-7-S O X 9 and pT7-7-S RY control DNA. Two-milliliter cultures of SOX13(66-604) were grown for 6 h before isopropylthiogalactoside induction, and 5-ml cultures of SOX9 and the various SOX13 constructs were grown for 2-3 h before induction. Soluble extracts were prepared (19) , and protein expression of SOX13 was confirmed by Western blot analysis using SOX13 antisera and T7-tag antibody (Novagen, Madison, WI). The amount of recombinant SOX13 protein was estimated by titration against bovine serum albumin on Coomassie blue stained SDS-PAGE gels. For production of The two preparations gave similar results, and so the data were combined. The sera had previously been collected and tested for anti-GAD and anti-IA-2 for other studies (21) (22) (23) . The sera were from 188 subjects with type 1 diabetes with a mean ± SD age at diagnosis of 29 ± 16 years and a duration of diabetes of 10 ± 11 years; 81 subjects with type 2 diabetes with a mean age at diagnosis of 52 ± 14 years and duration of 8 ± 7 years; and 175 healthy control subjects. Diagnoses were according to World Health Organization criteria (24), and use of the sera was approved by the Monash University Standing Committee on Ethics in Research on Humans. To compensate for variations between different batches of labeled proteins, a single reference serum was included in each assay, and the activity of each serum was expressed as reference units (RU) calculated as a percentage of the activity of the reference after correction for nonspecific binding. A positive result was defined as greater than the mean + 2 SD of the control subjects. Sera with ≥80 RU were considered to have high levels of antibody. Mapping of the antibody epitopes of SOX13. Recombinant proteins were purified by T7-tag antibody affinity chromatography (Novagen, Madison, WI), separated by 10% SDS-PAGE, and transferred to nitrocellulose filters. Filter strips were blocked in 5% skim milk powder and then incubated with doubling dilutions of disease sera at a 1:200 dilution. Bound antibody was detected using horseradish peroxidase (HRP)-conjugated anti-human immunoglobulins (Silenus, Hawthorn, Australia) and color development. Bacterial lysates containing the HMG domain of two other SOX proteins, SRY and SOX9, were prepared (25) and Western blotted in the same manner. RNA analysis. A multiple tissue Northern blot (Clontech, Palo Alto, CA) containing poly A+ RNA derived from adult human was hybridized at 50°C as d e s c r i b e d (26) using 2 salt sodium phosphate EDTA with a SOX13 370-bp fragment (encoding SOX13 amino acids 209-334). One hundred nanograms of the probe was radiolabeled by random priming with [ -3 2 P]dCTP (NEN, Boston, MA) and purified through a G-25 Sephadex spin column. The membrane was rehybridized with 50 ng of a c t i n probe (Clontech). The blot was exposed to a phosphorimaging screen for 24 h and 30 min for the S O X 1 3 and a c t i n probes, respect i v e l y, and bands were quantitated using the STORM phosphorimager (Molecular Dynamics, Sunnyvale, CA). Production of SOX13 antisera. The SOX13-specific peptide C-SQEKLDFNRN L K E V V PAIEKLLSS (amino acids 80 to 103) was synthesized and coupled to keyhole limpet hemocyanin (KLH) through the NH 2 -terminal cysteine using m-m a l e i m i d o b e n z o y l-N -hydroxysuccinimide. Rabbits were injected subcutaneously with 100 µg KLH-SOX13 peptide conjugate in 1 ml Freund's complete adjuvant and in Freund's incomplete adjuvant for the five subsequent monthly boosts. IgG was purified by Protein A Sepharose chromatography, and anti-peptide antibodies were isolated by affinity chromatography using activated CH-Sepharose conjugated to SOX13 (80-103) peptide (27) .
I m m u n o h i s t o c h e m i s t r y.
Unstained formalin fixed, paraffin-embedded human tissues mounted on poly-L-lysine coated slides Code T1065 (DAKO, Carpinteria, CA) or formalin fixed mouse tissues were stained with S O X 1 3 primary antibody at 1:200, 1:1,000, and 1:2,000 dilutions. Detection was by standard avidin/biotin immunohistochemical methods using biotin-conjugated anti-rabbit IgG and streptavidinconjugated HRP and development with diaminobenzidine (DAB). Specific S O X 1 3 expression was confirmed by blocking the reactivity with 10 -5 mol/l SOX13 (80 to 103) peptide and by the use of a preimmune serum control. After immunostaining and DAB development for SOX13, mouse pancreas sections were stained for insulin using guinea pig anti-porcine insulin code no. A564 (DAKO, Carpinteria, CA) and fluorescein isothiocyanate (FITC) conjugated anti-guinea pig IgG product no. F-7762 (Sigma, St. Louis, MO) according to the manufacturer's instructions. Image analysis software (MicroComputer Imaging Device; Imaging Research, St. Catharines, ON, Canada) was used to derive a bright field image of the DAB SOX13 staining artificially colored red and a dark field fluorescent image of the FITC insulin staining artificially colored green. The two images were overlayed to demonstrate colocalization. Biochemical analysis of recombinant SOX13. Approximately 10 fmol of SOX13(66-604) and SOX13 LZ-Q(327-604) proteins or control SOX9 HMG domain were separated by 10% SDS-PAGE and transferred onto a nitrocellulose fil t e r. For Western blot analysis, the membrane was blocked and the proteins SOX13(66-604) and SOX13 LZ-Q were detected using 2 ng/µl T7 antibody. The bound protein was detected using HRP-conjugated rabbit anti-mouse IgG at a dilution of 1:10,000 (Silenus, Hawthorn, Australia). The blot was developed using an ECL Plus kit (Amersham, Arlington Heights, IL) and was exposed to X-ray fil m for 15 min at room temperature. The far Western blot procedure (28) S -S O X 1 3 LZ-Q. The membranes were rinsed twice with AC buffer, then twice with AC buffer/1 m m o l / l dithiothreitol/2% skim milk powder for 1 min, followed by four 1-min washes in AC buffer. The blots were exposed to X-ray film for 2 days at -70°C. Electrophoretic mobility shift assay. Double stranded oligonucleotides
containing the SRY/SOX protein consensus binding motifs AACAAT and negative control CCGCGG, respectively (29) , were used for the electrophoretic mobility shift assay. Probes were labeled by a fill-in reaction using AMV Reverse Transcriptase (Promega) and [ - 
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SOX13 e n c o d e s I C A 1 2 . The DNA sequence of the ICA12 cDNA and 5 RACE products indicate a mRNA transcript length of 3,577 bp (Fig. 1A) . The SOX13 sequence has been submitted to Genbank under accession code AF116571. A single open reading frame of 604 amino acids contains a leucine heptad repeat (leucine zipper domain) adjacent to a region rich in glutamine (20 of 39 amino acids), an HMG domain, and an acidic COOH-terminal (16/40 amino acids) (Fig. 1B) . Sequence comparisons reveal a high degree of amino acid sequence similarity to the amino acid sequence deduced from the mouse Sox13 described by Kido et al. (12) throughout the entire 595 amino acid open reading frame (Fig. 1C) , indicating that the ICA12 cDNA is the human homologue of Sox13 from mouse. However, our identification of a 604 amino acid open reading frame for ICA12, called SOX13 herea f t e r, is in conflict with a recent report by Roose et al. SOX13 shares high amino acid similarity to Sox23 from rainbow trout (32) and to Sox12 from Xenopus (33) (Fig. 1C) , which are more similar to SOX13 than to any other SOX protein. Hence, mouse Sox13, rainbow trout Sox23, and X e n o p u s Sox12 may be orthologues of human SOX13. The leucine zipper/glutamine-rich region and the HMG domain of these proteins are highly similar, suggesting a functional role in vertebrates. Among mammals, the SOX13 HMG domain sequence shows 90% identity to SOX5 and Sox6 (Fig. 1D) and therefore belongs to the class D subgroup of SOX proteins, which also contain leucine zipper and glutamine-rich regions. SOX13 immunological reactivity in type 1 diabetes sera. Autoantibodies to SOX13 were detected in sera by radioimmunoprecipitation (RIP). Reactivity to SOX13 was s i g n i ficantly increased in type 1 diabetic patients compared with control subjects, being present in 34 of 188 (18%) patients with type 1 diabetes and in 8 of 175 (4.6%) nondiabetic control subjects (P = 0.0001, 2 -test with Yates' correction; F i g . 2A). The frequency of 6.2% (5 of 81) in type 2 diabetes was s i g n i ficantly lower than in type 1 diabetes (P = 0.018), but not s i g n i ficantly different from control subjects (P = 0.81). We conclude that serological anti-SOX13 reactivity is associated with autoimmune type 1 diabetes. Overall, 78% of the diabetic sera were positive for anti-GAD and 30% were positive for anti-IA-2. Eleven of the 33 anti-SOX13 positive sera were negative for both anti-GAD and anti-IA-2, indicating that anti-SOX13 does commonly occur in the absence of the other autoantibody reactivities associated with type 1 diabetes. The remaining 22 anti-SOX13 positive sera were positive for anti-GAD, and 6 of these were also positive for anti-IA-2.
To define the immunoreactive region(s) of SOX13, sera were further tested by RIP using truncated versions of SOX13 (Fig. 2B) . Eight of fifty sera from subjects with type 1 diabetes reacted with SOX13(66-604), of which the three with the highest level of antibody reactivity by RIP also reacted with SOX13(327-604). This suggests that autoantibodies are directed to at least two epitopes, one that requires amino acids 66-604 of SOX13, and a second confined within amino acids 327-604 that lacks the LZ-Q domains but includes the HMG domain. Five sera with high levels of antibody reactivity to SOX13 were tested by Western blot for reactivity against the HMG domains of recombinant SRY and SOX9, and all were negative (results not shown).
To directly demonstrate autoantibody reactivity to SOX13, seven sera from subjects with type 1 diabetes positive by RIP to SOX13(66-604) were further tested by Western blotting, using affinity-p u r i fied SOX13(66-604) as antigen. Figure 2C shows that four sera strongly positive by RIP detected the 6 6-kDa band, whereas three sera with lower levels of antibody by RIP did not. One serum that reacted with SOX13(327-604) and SOX13(66-604) by RIP did not bind SOX13(66-604) on the Western blot; the seven control sera also showed no reactivity. Expression of SOX13. A single 4.2-kb S O X 1 3 transcript was detected in all human tissues examined by Northern blot analysis (Fig. 3A) . Quantitation of this band versus a c t i n indicated that expression was highest in the pancreas, placenta, and kidney. Immunohistochemical analysis of human pancreas with a SOX13 antisera showed staining in the cytoplasm of a population of cells within the islets of Langerhans as well as isolated cells in the exocrine pancreas 
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( F i g . 3B). The immunostaining was blocked by the peptide used to raise the antisera (data not shown). Double labeling with antibodies to SOX13 and insulin was performed on sections of mouse pancreas. Sox13 staining was apparent in the islets of Langerhans in the cytoplasm of some islet cells, as was also seen in the human islets. In the mouse islets, howe v e r, there were also islet cells that showed distinct nuclear staining; many of these cells also expressed insulin (Fig. 3C ) . This indicates that Sox13 is expressed in islet -cells as well as in other islet cell types. SOX13 protein dimerization and DNA binding. D i m e rization potential of SOX13 was investigated using bacterial recombinant T7 epitope-tagged SOX13 (amino acids 66-604) and a deletion derivative of SOX13 lacking the leucine zipper domain and glutamine-rich region (SOX13 LZ-Q). A We s t e r n blot probed with T7 antibody revealed a 66-kDa band for SOX13(66-604) and a 43-kDa band for SOX13 LZ-Q (Fig. 4A,  lanes 1 and 2) . To test if SOX13 can form homodimers, renatured Western blots were probed with (Fig. 4A, lanes 3 and 4) , whereas the 3 5 S-S O X 1 3 LZ-Q probe failed to detect either protein ( F i g . 4A, lanes 6 and 7). The pattern of proteolytic products of SOX13(66-604) detected by the antibody to the NH 2 -t e rminal, T7 epitope was identical to that detected by 3 5 S-SOX13(66-604) ( F i g . 4A , lanes 1 and 3) , which is consistent with the presence of an NH 2 -terminal dimerization domain. These data indicate that SOX13 can form homodimers via the leucine zipper/glutamine-rich region.
Recombinant SOX13 was tested for binding to radiolabeled double-stranded DNA bearing the high-affinity SOX binding motif AACAAT (29, 34, 35) . SOX13(66-604) protein bound the AACAAT sequence but not the CCGCGG sequence ( F i g . 4B, lanes 5 and 2), which is consistent with the DNA binding specificity of other SOX proteins. However, the DNA binding activity of SOX13 was very low, as micromolar concentrations of protein were required for detectable complex formation. Given that DNA binding activity of rainbow trout Sox23 is completely inhibited by the presence of its leucine zipper region (31) 5-7) . Control sera from healthy individuals are shown in lanes 8 a n d 9. Lane 10 was probed with a rabbit antiserum raised to G S T-S O X 1 3 ( 3 2 6 -6 0 4 ) .
SOX13(66-604) protein is required to bind an equivalent amount of DNA as 17 nmol/l SOX13 LZ-Q (Fig. 4B, lanes 5  a n d 6) . A SOX13 antibody raised to a peptide located NH 2 -t e rminal to the leucine zipper domain further retards the migration of the SOX13/DNA complex (Fig. 4B , lane 10) , indicating that SOX13(66-604) binds DNA, albeit weakly, with an intact leucine zipper domain and consequently as a homod i m e r. We conclude that SOX13 forms a homodimer through its leucine zipper/glutamine-rich region and that dimerization causes a 70-fold reduction in DNA binding activity by its HMG domain.
D I S C U S S I O N
We have demonstrated that the S O X 1 3 gene encodes the t y p e 1 diabetes autoantigen ICA12 and has the biochemical properties of a transcription factor. Antibodies to SOX13 are present in sera from 18% of patients of type 1 diabetes, and the association of these autoantibodies with autoimmune diabetes was confirmed by the low frequency in subjects with type 2 diabetes and healthy control subjects. The dominant antibody epitope of SOX13 requires the majority of the protein, which may be a consequence of dimerization. This suggests that the intact protein, rather than degradation products, is autoantigenic. Similarly, autoantibodies to GAD recognize a conformational epitope and a dimeric config uration of the antigen (36, 37) . Whether autoimmunity to SOX13 is a component of disease pathogenesis or reflects an autoantibody reaction to sequestered SOX13 that is exposed to the immune system due to -cell destruction remains to be determined. The prevalence of autoantibodies to SOX13 is low in comparison to anti-GAD, anti-ICA512, and insulin autoantibodies, which occur in 60-80% of patients with type 1 diabetes (38, 39) and have proven to be predictive for the future development of the disease in healthy individuals (22, 38, (40) (41) (42) . H o w e v e r, it is worth noting that antibodies to SOX13 can occur independently of these other autoantibody reactivities (43) and so may prove a useful addition to a panel of autoantibody reactivities for the identification of individuals at high risk of developing the disease.
The expression of SOX13 in the -cells of the islets of Langerhans is consistent with an autoimmune response to SOX13 in type 1 diabetes, which is characterized by autoantibody responses to a variety of islet-cell components (1-4). SOX13 is also widely expressed in other tissues, particularly the heart and placenta, which may reflect expression in the walls of both large and small arteries as observed in the mouse (13) . This expression profile in human tissues differs from that of other type 1 diabetes autoantigens, such as GAD, ICA512/IA-2, carboxypeptidase H, and the GM2-1 ganglioside, which are expressed solely in pancreatic islets and other neuroendocrine tissues (44) (45) (46) (47) .
SOX13 has the required characteristics to act as a transcription factor. Sequence comparisons among vertebrates point to functional roles for the leucine zipper/glutaminerich region and HMG domains of SOX13. SOX13 contains an unusual leucine zipper motif of the form LX 5 Q L X 5 Q L X 5 Q L , which may mediate specific protein-protein interactions during nuclear import and transcriptional regulation through heterodimerization. In rainbow trout Sox23, the leucine zipper interacts with nucleoporin p62, which in turn interacts with the nuclear pore complex (32) . We have demonstrated that SOX13 can form homodimers through the leucine zipper/glutamine-rich region and that homodimerization significantly reduces DNA binding. Sox6 and rtSox23 homodimerize through their leucine zippers, which eliminates (48) . In contrast, we detect residual DNA binding activity by SOX13 homodimers. Heterodimerization of SOX5-SOX6 greatly increases their DNA binding and the subsequent activation by SOX9 at the Col2a1 enhancer (49) . By analogy with SOX5 and SOX6, heterodimerization with unknown leucine zipper proteins may modulate SOX13 activity in vivo. Immunohistochemistry indicates that SOX13 protein can be localized to the cytoplasm as well as the nucleus. In general, SOX proteins tend to localize to the nucleus, the site of DNA binding, although cytoplasmic staining of SOX9 has been reported (50) . Because SOX13 binds DNA poorly as a d i m e r, dimerization may hinder access of the HMG domain to DNA. Furthermore, the nuclear localization signal shared by SOX protein HMG domains (51) may also be obscured in the SOX13 homodimer. Exposure of the nuclear localization signal to importins may be facilitated through heterodimerization with factors such as p62 nucleoporin, which is known to interact with rtSox23 (32) .
The identification of SOX13 as an islet-cell autoantigen further characterizes the autoimmune response in type 1 diabetes and may advance the development of comprehensive diagnostic tests for identifying subjects at risk of developing the disease. Furthermore, the biochemical properties of SOX13 suggest a functional role for this protein as a transcription factor. 
